Aleena Alex1, Dhandapani Chidambaram2*, J Venugopal3 and M Mohan4*
1Department of Pharmacy Practice, KMCH College of Pharmacy, Coimbatore, Tamil Nadu, India
2Associate Professor, Department of Pharmacy Practice, KMCH College of Pharmacy, (Affiliated to The Tamil Nadu Dr. M.G.R. Medical University), Coimbatore, Tamil Nadu, India
3Department of Pulmonology, KMCH Coimbatore, Tamil Nadu, India
4Department of Cardiology, KMCH Coimbatore, Tamil Nadu, India
*Corresponding Author: Dhandapani Chidambaram, Associate Professor, Department of Pharmacy Practice, KMCH College of Pharmacy, (Affiliated to The Tamil Nadu Dr. M.G.R. Medical University), Coimbatore, Tamil Nadu, India.
Received: April 02, 2020; Published: May 13, 2020
Background: Chronic obstructive pulmonary disease (COPD) is characterized by progressive airﬂow constraint and is highly prevalent disease which may cause functional disability. The use of dual bronchodilator plays major role in the management of chronic obstructive pulmonary disease. Both short acting and long acting bronchodilator combinations are very effective for moderate to severe COPD. Cardiovascular changes in patients with chronic obstructive pulmonary disease (COPD) with the use of these combination drugs are important for improving treatment decisions.
Objectives: To check the cardiovascular risk and safety of using combination therapy with long acting β2 - agonist and long acting anticholinergics in COPD patients. To evaluate the adherence while using inhaler and educate about inhaler technique.
Method: It is a prospective observational study, patients aged more than 18 years who were diagnosed with COPD and those who received inhalation therapy included glycopyrronium and indacaterol included in the study.
Results: A total of 50 patients included in the study. The main parameters were monitored included ECG, Heart rate, Blood pressure. The patient’s blood pressure level mainly in the prehypertensive level. By considering the heart rate level of patient variation of heart rate in each visit can be seen. The comparison of each visits shows the significant changes for the heart rate variation. Out of 50 patients majority of patients are having abnormal ECG (88%). The main abnormality found in the ECG findings was sinus tachycardia (26%). The adherence of patients during each visit by showing the video of inhaler technique, among 50 patients 44 were counseled by video demonstration and rest of 6 patients by orally. The improvement of patients adherence level by showing the significant value (0.000).
Conclusion: The cardiovascular safety of this combination drug is harmless to an extent. The changes in blood pressure, heart rate and ECG is appear to safely tolerated and slight changes in these parameters are due to weakness and the effect of the drug in related to the response of patient’s different body characteristics. Proper inhalation technique gives the patients to take the inhaler confidently by knowing the better way of its usage.
Keywords: COPD; Bronchodilator; Inhalers; Combination Drug; ECG
Citation: Dhandapani Chidambaram., et al. “Assessment of Safety in COPD Patients Receiving Long Acting β2- agonist in Addition to Long Acting Anticholinergics". Acta Scientific Microbiology 3.6 (2020): 69-79.
Copyright: © 2020 Dhandapani Chidambaram., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.